62071-41-4

Upstream product

• 444341-90-6 4-[4-(benzyloxy)phenyl]tetrahydro-2H-pyran-4-ol 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 6793-92-6 p-benzyloxyphenylbromide 
• 106-41-2 4-bromo-phenol 
• 13139-86-1 4-methoxyphenyl magnesium bromide 
• 914365-66-5 4-(4-methoxyphenyl)-3,6-dihydro-2H-pyran 
• 1023937-38-3 4-(4-methoxyphenyl)tetrahydro-2H-pyran 
• 19578-68-8 4-(4-benzyloxyphenyl) iodide 
• 287944-16-5 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyran 

Downstream Products

• 62071-42-5 4-(4-hydroxy-3-chlorophenyl)-tetrahydropyran 
• 444341-89-3 3-bromopropyl 2-chloro-4-(4-tetrahydropyranyl)phenyl ether 
• 314051-16-6 2-Propyl-4-(4-tetrahydropyranyl)phenol 
• 65449-23-2 ethyl 4-(4'-tetrahydropyranyl)-phenoxy-acetate 
• 62071-35-6 ethyl 2-[4'-(4-tetrahydropyranyl)-phenoxy]-propanoate 
• 62071-32-3 2-methyl-2-[p-(4-tetrahydropyranyl)-phenoxy]-propanoic acid 
• 1121526-78-0 4-(tetrahydro-2H-pyran-4-yl)cyclohexanol 
• 1121526-79-1 4-(tetrahydro-2H-pyran-4-yl)cyclohexanone 

Relevant academic research and scientific papers

SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS

A chemical entity of Formula (I) or Formula (II): wherein Ra, Rb, Re, and Rf have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

MACROCYCLIC INDOLE DERIVATIVES

The present invention relates to macrocyclic indole derivatives of general formula (I) : (I), in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

HETEROCYCLIC COMPOUND

The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the f

N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6- carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration

Cannabinoid CB1 receptor agonists exhibit potent analgesic effects in rodents and humans, but their clinical utility as analgesic drugs is often limited by centrally mediated side effects. We report herein the preparation of N-methyl-3-(tetrahy

Novel Compounds 002

Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein R1, R2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

(2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARα agonists as hypolipidemic agents

A SAR study was conducted on chromane-2-carboxylic acid toward selective PPARα agonisim. As a result, highly potent, and selective PPARα agonists were discovered. The optimized compound 43 exhibited robust lowering of total cholesterol levels in hamster and dog animal models.

Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders

A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, d

Arylthiazolidinedione derivatives

Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridem

Novel p-(4-tetrahydropyranyl)-phenoxy-compounds

Novel pyranic derivatives of the formula STR1 wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and cations of alkali metals, alkaline earth metals, aluminum, amines and ammonium R1 and R2 are